menu search

ZLAB / Why Shares of Zai Lab Are Dropping Wednesday

Why Shares of Zai Lab Are Dropping Wednesday
Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study. Read More
Posted: Jun 7 2023, 11:05
Author Name: The Motley Fool
Views: 092195

ZLAB News  

Zai Lab Stock: De-Risking Through Market Tapping

By Seeking Alpha
September 7, 2023

Zai Lab Stock: De-Risking Through Market Tapping

Zai Lab Limited is a biotech company that acts as a powerful partner for other biotechs to launch drug candidates in China. They currently distribute more_horizontal

Zai Lab Announces Participation in September Investor Conferences

By GlobeNewsWire
August 29, 2023

Zai Lab Announces Participation in September Investor Conferences

SHANGHAI, China and CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the more_horizontal

Zai Lab: LUNAR Trial Paves Way For New Therapies

By Seeking Alpha
July 26, 2023

Zai Lab: LUNAR Trial Paves Way For New Therapies

Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a more_horizontal

Why Shares of Zai Lab Are Dropping Wednesday

By The Motley Fool
June 7, 2023

Why Shares of Zai Lab Are Dropping Wednesday

Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study. more_horizontal

Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today

By The Motley Fool
May 22, 2023

Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today

Many Wall Street analysts still see an economic recovery playing out in China. President Biden recently said he expects relations with China to improv more_horizontal

1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off

By The Motley Fool
March 26, 2023

1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off

Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has en more_horizontal

2 Growth Stocks With Incredible Potential in the Next 5 Years

By The Motley Fool
March 6, 2023

2 Growth Stocks With Incredible Potential in the Next 5 Years

Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy. more_horizontal

3 More Mid-Cap Biotechs The Street Sees Doubling

By MarketBeat
February 22, 2023

3 More Mid-Cap Biotechs The Street Sees Doubling

Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based more_horizontal


Search within

Pages Search Results: